Malignant Pleural Mesothelioma: Present Status and Future Directions

Malignant pleural mesothelioma is a life-threatening neoplasm of the mesothelium, the layer of tissue that covers many organs in the human body. The incidence of this type of neoplasm is gradually ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Lung Sparing Surgery for Malignant Pleural Mesothelioma

Pp. 429-440 (12)

Robert B. Cameron

Abstract

Malignant pleural mesothelioma is a diffuse tumor that does not easily lend itself to surgical resection. However, there are several observations that seemingly support the use of surgery in this disease. A variety of surgical procedures have been utilized in an attempt to provide the maximum therapeutic benefit to patients with malignant pleural mesothelioma. They vary from a small thorascopic pleurodesis procedure to a radical extrapleural pneumonectomy. Pleurectomy/decortication (P/D) and partial pleurectomy, have been used in many centers as an alternative procedure in patients who cannot undergo extrapleural pneumonectomy (EPP). Mortality of partial pleurectomy and P/D ranges between 0% and 8%. Survival statistics showed a slight trend for longer disease-free survival in extended P/D versus P/D, but there were no differences in median overall survival. Partial pleurectomy appeared to be inferior, with an overall median survival ranging from 7.1 to 14 months. Overall, current evidence supports the claim that P/D produces similar or better outcomes than EPP. The results of the Mesothelioma And Radical Surgery 2 trial will hopefully provide a stronger evidence on these topics.

Keywords:

Extrapleural pneumonectomy, pleurectomy/decortication, partial pleuroectomy.

Affiliation:

UCLA, Cardiothoracic Surgery and Surgical Oncology, Los Angeles, Jonsson Comprehensive Cancer Center, 757 Westwood Plaza, Los Angeles, CA 90095, United States.